FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely to a method for the treatment of persistent intraretinal or subretinal edema caused by exudative AMD despite the previous treatment with intravitreal anti-VEGF in a human subject, while the method includes the injection to a human subject of the effective amount of a liquid composition by intravitreal injection for the treatment of persistent intraretinal or subretinal edema, where the liquid composition contains from 1 to 10 wt./wt.% of sirolimus or its pharmaceutically acceptable salt.
EFFECT: invention provides for a method for the treatment of persistent edema in patients with exudative AMD.
14 cl, 6 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| METHOD FOR PREDICTING RESPONSE TO REPEATED ANTI-VEGF THERAPY IN CHOROIDAL NEOVASCULARIZATION IN AMD | 2022 |
|
RU2788971C1 |
| METHOD OF TREATING EYE DISEASES | 2015 |
|
RU2722643C2 |
| METHOD FOR TREATMENT OF EYE DISEASES | 2015 |
|
RU2771900C2 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF SUBRETINAL FIBROSIS IN PATIENTS WITH EXUDATIVE FORM OF AGE-RELATED MACULAR DEGENERATION GIVEN ANTI-VEGF THERAPY | 2022 |
|
RU2793419C1 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| METHODS FOR TREATMENT OF EYE DISEASES | 2019 |
|
RU2776850C2 |
| COMPOSITIONS AND METHODS OF TREATING AND PREVENTING MACULAR DEGENERATION | 2015 |
|
RU2703145C2 |
| METHOD FOR SELECTING THERAPEUTIC APPROACH TO AGE-RELATED MACULAR DEGENERATION (AMD) | 2018 |
|
RU2707955C1 |
| METHOD FOR THE TREATMENT OF ACTIVE CHOROIDAL NEOVASCULAR MEMBRANES OF EXTRAFOVEAL LOCALIZATION | 2022 |
|
RU2777739C1 |
